Inclusion Criteria

Concurrent Medication:

Required:

• Zidovudine (AZT) during treatment and for 20 weeks after the last infusion unless medically contraindicated.
• Allowed:
• Aerosolized pentamidine for Pneumocystis carinii pneumonia (PCP) prophylaxis.
• Oral antibiotics for PCP prophylaxis if hematologically stable on that regimen for at least 30 days prior to study entry.

Patients must have the following:

• Positive HIV antibody test by federally licensed ELISA.
• Positive HIV culture or plasma p24 antigen.
• CDC Group IV severe AIDS-related complex (ARC) or AIDS.
• Must have been on zidovudine (AZT) at least 6 weeks prior to infusion and agree to continue this medication during the study and for 20 weeks after the last infusion unless medically contraindicated.
• Allowed:
• Kaposi's sarcoma.

Exclusion Criteria

Co-existing Condition:

AMENDED:

• Pulmonary diseases that require treatment.
• AMENDED:
• Significant central nervous system disease including AIDS dementia, psychiatric disabilities, or seizure disorders.
• AMENDED:
• Symptomatic HIV CNS infections or symptoms compatible with HIV encephalopathy.
• Original design:
• Patients with the following conditions or symptoms are excluded:
• Active bacterial or opportunistic infection that requires treatment.
• Neoplasms not specifically allowed, basal cell carcinoma of the skin, or in-situ carcinoma of the cervix.
• Clinically significant cardiac (= or > class II, New York Heart Association) or peripheral vascular disease that requires treatment.
• Hemorrhagic diathesis including hemophilia or active bleeding disorder.

Concurrent Medication:

Excluded:

• Antineoplastic therapy.
• Medication required for treatment of active cardiac disease.
• Cardiac glycosides.
• Antiarrhythmics.
• Antianginal agents.
• Anticoagulants.
• Thrombolytic agents.
• Vasodilators.
• Excluded within 30 days of study entry:
• Antiretroviral agents not specifically allowed.
• Corticosteroids.
• Acyclovir.
• Excluded within 60 days of study entry:
• Biological response modifiers.

Patients with the following are excluded:

• Unable to give properly informed consent by reason of impaired mentation.
• Diseases and conditions specified elsewhere in the protocol.

Required:

• Zidovudine (AZT) for at least 6 weeks prior to infusion.

Risk Behavior: Excluded:

• Active substance abuse.